Form 4: Biodesix Director Hany Massarany Receives Equity Awards

Biodesix Director Hany Massarany was granted 7,484 Restricted Stock Units and options for 6,354 shares of common stock.

Summary

• Hany Massarany, a Director of Biodesix Inc. (BDSX), reported the acquisition of equity securities.
• The transaction date for these acquisitions was January 2, 2026.
• Massarany received 7,484 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of the Issuer's common stock.
• These RSUs will vest in four equal installments on March 31, June 30, September 30, and December 31, 2026, subject to continued service.
• The shares underlying these RSUs will be issued to Massarany following his separation from service with the Issuer.
• Massarany also acquired options to buy 6,354 shares of common stock with an exercise price of $6.46 per share.
• These stock options will vest in four substantially equal installments on March 31, June 30, September 30, and December 31, 2026, also subject to continued service.
• The stock options have an expiration date of January 1, 2036.

Sentiment

Score: 6

Explanation: The filing reports standard equity compensation for a director, which is a neutral to slightly positive event as it aligns their interests with shareholders. It does not contain information that would significantly alter the investment thesis for Biodesix.

Positives

• The grant of Restricted Stock Units and stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining experienced board members.

Risks

• The vesting of both the Restricted Stock Units and stock options is generally subject to the Reporting Person's continued service with the Issuer, meaning the awards could be forfeited if service ceases prematurely.

Future Outlook

The future outlook indicates that Director Hany Massarany's equity ownership in Biodesix will increase over 2026 as his Restricted Stock Units and stock options vest, contingent upon his continued service to the company.

Industry Context

Equity grants to directors are a common form of compensation in the biotechnology and diagnostics industry, aiming to align leadership incentives with shareholder value creation. This practice is standard across publicly traded companies to attract and retain qualified board members.

Comparison to Industry Standards

• The grant of Restricted Stock Units and stock options to a director is a standard compensation practice within the U.S. public company landscape, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule over approximately one year is typical for annual equity grants to non-employee directors, similar to practices seen at companies like Guardant Health (GH) or Exact Sciences (EXAS) for their board members.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with shareholder value, potentially leading to more focused decision-making for long-term growth.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The Restricted Stock Units and stock options will vest in four installments on March 31, June 30, September 30, and December 31, 2026, subject to continued service.

Key Dates

Recommendation

The filing reports standard equity compensation for an existing director, which is a routine event and does not provide new information significant enough to warrant a change in investment recommendation. It aligns the director's interests with shareholders but does not reflect operational performance or strategic shifts that would impact a 'buy' or 'sell' decision.

Keywords

Biodesix, BDSX, Hany Massarany, Form 4, SEC filing, Restricted Stock Units, Stock Options, Director compensation, Equity award, Insider transaction